{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Double-dummy+placebo&page=2",
    "query": {
      "intervention": "Double-dummy placebo",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 370,
    "total_pages": 37,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Double-dummy+placebo&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Double-dummy+placebo&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T01:34:10.618Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00669617",
      "title": "Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Indacaterol",
          "type": "DRUG"
        },
        {
          "name": "Salmeterol/fluticasone (50/500 μg)",
          "type": "DRUG"
        },
        {
          "name": "Salbutamol (200 µg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Indacaterol",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Salmeterol/fluticasone",
          "type": "DRUG"
        },
        {
          "name": "Placebo to salbutamol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2008-04",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2011-09-12",
      "last_synced_at": "2026-10-02T01:34:10.618Z",
      "location_count": 5,
      "location_summary": "Tamarac, Florida • Lafayette, Louisiana • Saint Charles, Missouri + 2 more",
      "locations": [
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Lafayette",
          "state": "Louisiana"
        },
        {
          "city": "Saint Charles",
          "state": "Missouri"
        },
        {
          "city": "Shelby",
          "state": "North Carolina"
        },
        {
          "city": "Beaver",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00669617"
    },
    {
      "nct_id": "NCT01427283",
      "title": "A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Low Back Pain"
      ],
      "interventions": [
        {
          "name": "Oxycodone/Naloxone controlled-release",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone HCl controlled-release",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Purdue Pharma LP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 450,
      "start_date": "2011-08",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2015-02-12",
      "last_synced_at": "2026-10-02T01:34:10.618Z",
      "location_count": 149,
      "location_summary": "Alabaster, Alabama • Birmingham, Alabama • Foley, Alabama + 114 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01427283"
    },
    {
      "nct_id": "NCT03110900",
      "title": "Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Agitation,Psychomotor",
        "Haloperidol Causing Adverse Effects in Therapeutic Use",
        "Lorazepam Causing Adverse Effects in Therapeutic Use",
        "Loxapine Causing Adverse Effects in Therapeutic Use"
      ],
      "interventions": [
        {
          "name": "Haloperidol + lorazepam",
          "type": "DRUG"
        },
        {
          "name": "Loxapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 2,
      "start_date": "2017-09-30",
      "completion_date": "2018-04-04",
      "has_results": true,
      "last_update_posted_date": "2018-06-11",
      "last_synced_at": "2026-10-02T01:34:10.618Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03110900"
    },
    {
      "nct_id": "NCT01475461",
      "title": "Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "PF-04937319 - 3mg",
          "type": "DRUG"
        },
        {
          "name": "PF-04937319 - 20mg",
          "type": "DRUG"
        },
        {
          "name": "PF-04937319 - 50mg",
          "type": "DRUG"
        },
        {
          "name": "PF-04937319 - 100mg",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin - 100mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 345,
      "start_date": "2011-11",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2017-01-31",
      "last_synced_at": "2026-10-02T01:34:10.618Z",
      "location_count": 24,
      "location_summary": "Anaheim, California • Los Angeles, California • Spring Valley, California + 18 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Belleview",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01475461"
    },
    {
      "nct_id": "NCT02021773",
      "title": "Assessment of LBR-101 In Chronic Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Migraine"
      ],
      "interventions": [
        {
          "name": "LBR-101 High Dose",
          "type": "DRUG"
        },
        {
          "name": "LBR-101 Low Dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 264,
      "start_date": "2014-01-31",
      "completion_date": "2015-03-31",
      "has_results": true,
      "last_update_posted_date": "2021-12-09",
      "last_synced_at": "2026-10-02T01:34:10.618Z",
      "location_count": 57,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 51 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02021773"
    },
    {
      "nct_id": "NCT07595302",
      "title": "Comparing Pain Improvement for Intravenous Versus Oral Acetaminophen in Acute Pelvic Pain",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pelvic Pain"
      ],
      "interventions": [
        {
          "name": "Acetaminophen 1000mg PO",
          "type": "DRUG"
        },
        {
          "name": "IV Acetaminophen 1000mg",
          "type": "DRUG"
        },
        {
          "name": "IV Placebo",
          "type": "OTHER"
        },
        {
          "name": "PO Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Montefiore Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "16 Years to 50 Years · Female only"
      },
      "enrollment_count": 140,
      "start_date": "2026-11",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-02T01:34:10.618Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07595302"
    },
    {
      "nct_id": "NCT00479401",
      "title": "Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Early Parkinson Disease (Early PD)"
      ],
      "interventions": [
        {
          "name": "Pramipexol Extended Release",
          "type": "DRUG"
        },
        {
          "name": "Pramipexol Immediate Release",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 539,
      "start_date": "2007-05",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-07-17",
      "last_synced_at": "2026-10-02T01:34:10.618Z",
      "location_count": 16,
      "location_summary": "Gilbert, Arizona • Sun City, Arizona • La Jolla, California + 13 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Danbury",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00479401"
    },
    {
      "nct_id": "NCT04271475",
      "title": "A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Thromboembolic Pulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "Macitentan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 127,
      "start_date": "2020-07-07",
      "completion_date": "2023-12-21",
      "has_results": true,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-10-02T01:34:10.618Z",
      "location_count": 24,
      "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 20 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04271475"
    },
    {
      "nct_id": "NCT01768572",
      "title": "To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "sarilumab SAR153191 (REGN88)",
          "type": "DRUG"
        },
        {
          "name": "tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "leflunomide",
          "type": "DRUG"
        },
        {
          "name": "subcutaneous placebo",
          "type": "DRUG"
        },
        {
          "name": "intravenous placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 202,
      "start_date": "2013-03",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2017-06-26",
      "last_synced_at": "2026-10-02T01:34:10.618Z",
      "location_count": 14,
      "location_summary": "Huntsville, Alabama • Colorado Springs, Colorado • Aventura, Florida + 10 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01768572"
    },
    {
      "nct_id": "NCT01076764",
      "title": "Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Coronary Syndrome"
      ],
      "interventions": [
        {
          "name": "Otamixaban",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for Otamixaban)",
          "type": "DRUG"
        },
        {
          "name": "UFH",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for UFH)",
          "type": "DRUG"
        },
        {
          "name": "Eptifibatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for Eptifibatide)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13220,
      "start_date": "2010-04",
      "completion_date": "2013-05",
      "has_results": false,
      "last_update_posted_date": "2016-05-04",
      "last_synced_at": "2026-10-02T01:34:10.618Z",
      "location_count": 107,
      "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 82 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01076764"
    }
  ]
}